Logo image of PRPH

PROPHASE LABS INC (PRPH) Stock Fundamental Analysis

NASDAQ:PRPH - Nasdaq - US74345W1080 - Common Stock - Currency: USD

0.3307  +0.01 (+2.45%)

After market: 0.33 0 (-0.21%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PRPH. PRPH was compared to 198 industry peers in the Pharmaceuticals industry. PRPH has a bad profitability rating. Also its financial health evaluation is rather negative. PRPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PRPH has reported negative net income.
PRPH had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PRPH reported negative net income in multiple years.
PRPH had negative operating cash flow in 4 of the past 5 years.
PRPH Yearly Net Income VS EBIT VS OCF VS FCFPRPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.23%, PRPH is in line with its industry, outperforming 52.02% of the companies in the same industry.
PRPH has a Return On Equity of -72.80%. This is comparable to the rest of the industry: PRPH outperforms 47.47% of its industry peers.
Industry RankSector Rank
ROA -30.23%
ROE -72.8%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
PRPH Yearly ROA, ROE, ROICPRPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

PRPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRPH Yearly Profit, Operating, Gross MarginsPRPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRPH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PRPH has been increased compared to 5 years ago.
The debt/assets ratio for PRPH is higher compared to a year ago.
PRPH Yearly Shares OutstandingPRPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
PRPH Yearly Total Debt VS Total AssetsPRPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.17, we must say that PRPH is in the distress zone and has some risk of bankruptcy.
PRPH has a Altman-Z score (-1.17) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.29 indicates that PRPH is not too dependend on debt financing.
The Debt to Equity ratio of PRPH (0.29) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -1.17
ROIC/WACCN/A
WACC12.1%
PRPH Yearly LT Debt VS Equity VS FCFPRPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

PRPH has a Current Ratio of 1.47. This is a normal value and indicates that PRPH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.47, PRPH is doing worse than 70.71% of the companies in the same industry.
A Quick Ratio of 1.33 indicates that PRPH should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.33, PRPH is not doing good in the industry: 68.69% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.33
PRPH Yearly Current Assets VS Current LiabilitesPRPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

PRPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -138.78%.
Looking at the last year, PRPH shows a very negative growth in Revenue. The Revenue has decreased by -80.65% in the last year.
Measured over the past years, PRPH shows a decrease in Revenue. The Revenue has been decreasing by -7.32% on average per year.
EPS 1Y (TTM)-138.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.76%
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-157.09%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.59%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRPH Yearly Revenue VS EstimatesPRPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
PRPH Yearly EPS VS EstimatesPRPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRPH Price Earnings VS Forward Price EarningsPRPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRPH Per share dataPRPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROPHASE LABS INC

NASDAQ:PRPH (5/2/2025, 8:18:07 PM)

After market: 0.33 0 (-0.21%)

0.3307

+0.01 (+2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2025-03-31/bmo
Earnings (Next)05-08 2025-05-08
Inst Owners8.33%
Inst Owner Change5.2%
Ins Owners11.16%
Ins Owner Change0%
Market Cap13.85M
Analysts82.86
Price Target16.32 (4834.99%)
Short Float %3.31%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-494.95%
Min EPS beat(2)-957.84%
Max EPS beat(2)-32.05%
EPS beat(4)1
Avg EPS beat(4)-251.68%
Min EPS beat(4)-957.84%
Max EPS beat(4)75.49%
EPS beat(8)2
Avg EPS beat(8)-192.35%
EPS beat(12)5
Avg EPS beat(12)-110.27%
EPS beat(16)6
Avg EPS beat(16)-181.27%
Revenue beat(2)0
Avg Revenue beat(2)-82.68%
Min Revenue beat(2)-87.07%
Max Revenue beat(2)-78.3%
Revenue beat(4)0
Avg Revenue beat(4)-72.33%
Min Revenue beat(4)-87.07%
Max Revenue beat(4)-60.09%
Revenue beat(8)2
Avg Revenue beat(8)-38.18%
Revenue beat(12)6
Avg Revenue beat(12)-8.82%
Revenue beat(16)9
Avg Revenue beat(16)-7.03%
PT rev (1m)-13.51%
PT rev (3m)-13.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-366.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-87.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-84.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.09
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-2.34
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.3
BVpS0.91
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.23%
ROE -72.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.09%
Cap/Sales 19.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.33
Altman-Z -1.17
F-Score1
WACC12.1%
ROIC/WACCN/A
Cap/Depr(3y)42.96%
Cap/Depr(5y)127.08%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-138.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-211.76%
EPS Next Y75.59%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-157.09%
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-130.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.22%
OCF growth 3YN/A
OCF growth 5YN/A